In patients with recurrent prostate cancer, discriminating local or systemic recurrence is critical to decide second-line treatment. We investigated the capability of stereotactic body radiotherapy to treat limited nodal recurrences, detected using choline PET scan.
Methods and study design
Seventy-one patients with biochemical failure were studied after prostate cancer treatment: prostatectomy (28), radiotherapy (15) or both (28). Following computed tomography and choline PET imaging, stereotactic body radiotherapy was delivered on pathological lymphatic areas by 6 MV Linac, using dynamic micromultileaf collimation and intensity-modulated arc therapy optimization. Sixty days post-treatment, choline PET/CT imaging was carried out.
Results
Median follow-up was 29 months (range, 14.4–48). Choline PET detected recurrences in 39 of 71 patients. Median PSA velocity was 0.40 ng/ml/year in PET-negative patients and 2.88 ng/ml/year in PET-positive subjects (P <0.05). Twenty-five patients with limited nodal recurrences, out of the 71 submitted to choline PET, received eradicative radiotherapy. Persistent regression was recorded in 13; early spread to bone was found in 2 cases; lymph node recurrences in 8, all in sites outside the irradiated areas; 2 patients were lost to follow-up. At the 3-year follow-up, overall survival, disease-free survival and local control rates were 92%, 17% and 90%, respectively. In patients with a complete regression, PSA fell from 5.65 to 1.40 ng/ml (median). PSA nadir value (median 1.06 ng/ml) was maintained for 5.6 months (median).
Conclusions
Stereotactic body radiotherapy was effective in disease eradication of limited nodal recurrences from prostate cancer, saving patients from, or at least postponing, systemic treatments. Free full text available at www.tumorionline.it
ThoenyH.C., TriantafyllouM., BirkhaeuserF.D., FroehlichJ.M., TsheringD.W., BinserT., FleishmannA., VermalthenP., StuderU.E.: Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients.Eur Urol, 55: 761–769, 2009.
2.
BrigantiA., CapitanioU., ChunF.K., GallinaA., SuardiN., SaloniaA., Da PozzoL.F., ColomboR., Di GirolamoV., BertiniR., GuazzoniG., KarakiewiczP.I., MontorsiF., RigattiP.: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.Eur Urol, 54: 794–802, 2008.
3.
MatteiA., FuechselF.G., Bhatta DharN., WarnckeS.H., ThalmannG.N., KrauseT., StuderU.E.: The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study.Eur Urol, 53: 118–125, 2008.
4.
HeidenreichA., OhlmannC.H., PolyakovS.: Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.Eur Urol, 52: 29–37, 2007.
5.
GlundeK., AckerstaffE., MoriN., JacobsM.A., BhujwallaZ.M.: Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions.Mol Pharm, 3: 496–506, 2006.
BuyyounouskiM.K., HanlonA.L., EisenbergD.F., HorwitzE.M., FeigenbergS.J., UzzoR.G., PollackA.: Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.Int J Radiat Oncol Biol Phys, 63: 1455–1462, 2005.
10.
KarakiewiczP.: The rate of lymph node invasion (LNI) in men with PSA values less than 10 ng/ml.Eur Urol, 50: 277–278, 2006.
11.
OyamaN., MillerT.R., DehdashtiF., SiegelB.A., FischerK.C., MichalskiJ.M., KibelA.S., AndrioleG.L., PicusJ., WelchM.J.: 11C-Acetate PET imaging of prostate cancer; detection of recurrent disease at PSA relapse.J Nucl Med, 44: 549–555, 2003.
12.
AlbrechtS., BucheggerF., SolovievD., ZaidiH., VeesH., KhanH.G., KellerA., Bischof DelaloyeA., RatibO., MiralbellR.: (11)C-Acetate PET in the early evaluation of prostate cancer recurrence.Eur J Nucl Med Mol Imaging, 34: 185–196, 2007.
13.
SchillingD., SchlemmerH.P., WagnerP.H., BöttcherP., MerseburgerA.S., AschoffP., BaresR., PfannenbergC., GanswindtU., CorvinS., StenzlA.: Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.BJU Int, 102: 446–451, 2008.
14.
CarterH.B., PearsonJ.D., MetterE.J., BrantL.J., ChanD.W., AndresR., FozardJ.L., WalshP.C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.JAMA, 267: 2215–2220, 1992.
15.
D'AmicoA.V., ChenM., RoehlK.A., CatalonaW.J.: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.N Engl J Med, 351: 125–135, 2004.
16.
Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.Int J Radiat Oncol Biol Phys, 37: 1035–1041, 1997.
17.
CooksonM.S., AusG., BurnettA.L., Canby-HaginoE.D., D'AmicoA.V., DmochowskiR.R., EtonD.T., FormanJ.D., GoldenbergS.L., HernandezJ., HiganoC.S., KrausS.R., MoulJ.W., TangenC., ThrasherJ.B., ThompsonI.: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.J Urol, 177: 540–545, 2007.
MasiL., CasamassimaF., MenichelliC., PasciutiK., DoroR., PolliC., D'ImporzanoE., BonucciI.: On-line image guidance for frameless stereotactic radiotherapy of lung malignancies by cone beam CT: comparison between target localization and alignment on bony anatomy.Acta Oncol, 47: 1422–1431, 2008.
20.
CoxJ.D., StetzJ., PajakT.F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
21.
Da PozzoL.F., CozzariniC., BrigantiA., SuardiN., SaloniaA., BertiniR., GallinaA., BianchiM., FantiniG.V., BolognesiA., FazioF., MontorsiF., RigattiP.: Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.Eur Urol, 55: 1003–1011, 2009.
22.
ScattoniV., PicchioM., SuardiN., MessaC., FreschiM., RoscignoM., Da PozzoL., BocciardiA., RigattiP., FazioF.: Detection of lymph-node metastases with integrated (11C)choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.Eur Urol, 52: 423–429, 2007.
23.
de JongI.J., PruimJ., ElsingaP.H., VaalburgW., MensinkH.J.: 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer.Eur Urol, 44: 32–38, 2003.
24.
HeinischM., DirisamerA., LoidlW., StoiberF., GruyB., HaimS., LangstegerW.: Positron emission tomography/computed tomography with F-18–fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?Mol Imaging Biol, 8: 43–48, 2006.
25.
SinghD., YiW.S., BrasacchioR.A., MuhsA.G., SmudzinT., WilliamsJ.P., MessingE., OkunieffP.: Is there a favorable subset of patients with prostate cancer who develop oligometastases?Int J Radiat Oncol Biol Phys, 58: 3–10, 2004.
26.
PasquierD., BallereauC.: Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.Int J Radiat Oncol Biol Phys, 2: 972–979, 2008.
27.
KingC.R., BrooksJ.D., GillH., PawlickiT., CotrutzC., PrestiJ.C.Jr.: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.Int J Radiat Oncol Biol Phys, 73: 1043–1048, 2009.
28.
SandblomG., SörensenJ., LundinN., HäggmanM., MalmströmP.U.: Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy.Urology, 67: 996–1000, 2006.
29.
PicchioM., MessaC., LandoniC., GianolliL., SironiS., BrioschiM, MatarreseM., MateiD.V., De CobelliF., Del MaschioA., RoccoF., RigattiP., FazioF.: Value of (11C)choline-positron emission tomography for re-staging prostate cancer: a comparison with (18F)fluorodeoxyglucose-positron emission tomography.J Urol, 169: 1337–1340, 2003.
30.
KrejcarekS.C., ChenM.H., RenshawA.A., LoffredoM., SussmanB., D'AmicoA.V.: Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.Urology, 69: 515–519, 2007.
